Convalescent plasma (CP) and standard of care (SOC) did not result in a higher proportion of clinical improvement on at day 28 in hospitalised patients with COVID-19 compared to SOC alone.

This is an investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial.

Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or SOC alone.

The primary outcome was the proportion of patients with clinical improvement 28 days after enrolment.

A total of 160 (80 in each arm) patients (66.3% were critically ill and 33.7%, severe) completed the trial.

The median age was 60.5 years, 58.1% were men and the median time from symptom onset to randomisation was 10 days.

Neutralising antibodies titres >1:80 were present in 133 (83.1%) patients at baseline.

Read More